Personal injury lawsuit filed against makers of contaminated drug Heparin
CAMDEN, N.J. A personal lawsuit against Baxter Healthcare has been filed following a near fatal reaction to the contaminated prescription drug Heparin, according to published reports.
Accounts of deaths and hundreds of severe allergic reactions stemmed from an active ingredient in the drug, which was identified as a chemically altered form of chondroitin sulfate. According to published reports, the chemical serves as a dietary supplement made from animal cartilage that is used to treat joint pain.
The contamination was rooted in China, where the drug is manufactured. The Federal Drug Administration filed a report on March 19 alerting the public of the dangers of taking the Heparin, and the medications were almost immediately recalled as a result.
“Prescription drug manufacturers have a duty to produce products that are safe and free of dangerous ingredients,” stated Wendy Fleishman of the New York City office of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein. “Only through a lawsuit or otherwise making a claim against Baxter can patients obtain compensation for their injuries. The American public needs the drug companies, like Baxter, to take responsibility for the safety of their products—especially those like Heparin, which are manufactured in part in China.”
The suit claims that Baxter did not adequately inspect the product before selling it, making them negligent, and as a result contributing to many unnecessary deaths.
Rite Aid posts sales increase for March
CAMP HILL, Pa. Rite Aid on Thursday reported a same-store sales increase of 2.6 percent (which does not yet include the Brooks/Eckerd acquired stores) for the four weeks ended March 29.
Pharmacy same-store sales increased 1 percent, which included an approximate 493 basis points negative impact from new generic introductions. Front-end same-store sales were up 5.7 percent. March same store sales were positively affected by a shift to a March Easter this year from an April Easter last year (March 23 this year as compared to April 8 last year).
Total drug store sales for the four-week period increased 50.7 percent to $2 billion. Prescription revenue accounted for 67.6 percent of drugstore sales, and third party prescription revenue represented 96.2 percent of pharmacy sales.
FDA grants orphan designation for MELAS syndrome drug
WASHINGTON Sirtris Pharmaceuticals has been granted orphan drug designation for resveratrol by the Food and Drug Administration, according to published reports.
Resveratrol is a drug used to treat MELAS syndrome, a progressive fatal aging disease that produces symptoms of muscle weakness, fatigue, recurrent headaches and seizures. The government’s grant is usually offered in cases in which companies are discovering treatments for rare drugs, and the grant would allow the company to speed up their testing period.
Sitris has decided to focus on the SIRT1 gene, which is a gene tied to the aging process. SIRT1 is being studied as a possible source in treating MELAS or type 2 diabetes. According to published reports, the grant has resulted in Sitris being offered seven years of marketing exclusivity for its formulation of resveratrol.